AbbVie Seeks Eligible Participants for Clinical Research Study for Treatment of Small Cell Lung Cancer
You have completed your first time-line of chemotherapy for Small Cell Lung Cancer and now you are wondering about your next step. Consider the MERU STUDY.
If you are going through treatment for small cell lung cancer your main aim is to enjoy quality time with friends and family. If you have completed your first line chemotherapy and your cancer has stopped growing or slowed down you may be eligible to participate in a clinical trial. The trial is being conducted for patients who have had a successful response to initial chemotherapy. The trial aim is to determine if the investigational medicine called RovaT may improve your cancer and overall survival. In addition the trial will look into whether RovaT is safe for participants and how well participants will tolerate it.
You may be eligible to participate if:*
- You have been diagnosed with extensive stage Small Cell Lung Cancer
- Your cancer has remained stable or has improved following initial 4 cycles of chemotherapy
- You finished your last cycle of initial chemotherapy within the last 3 weeks
- Your doctor is not planning any radiotherapy, other than radiotherapy to the brain, after the last cycle of initial chemotherapy
*The study doctor can tell you about additional requirements to be able to participate in this study.
If you would like to be considered for this trial, call AbbVie on 011 831 3250 or email your query to firstname.lastname@example.org and you will be directed to a clinical research site where you will be assessed in order to determine eligibility.
Recruitment for this study will end in April 2019.
Please note, CANSA has no affiliation with, or involvement in, any clinical trials.